Premium
Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B‐cell lymphoma and its subtypes
Author(s) -
WatanukiMiyauchi Rumiko,
Kojima Yasushi,
Tsurumi Hisashi,
Hara Takeshi,
Goto Naoe,
Kasahara Seiji,
Saio Masanao,
Moriwaki Hisataka,
Takami Tsuyoshi
Publication year - 2005
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.2005.01832.x
Subject(s) - survivin , diffuse large b cell lymphoma , lymphoma , germinal center , monoclonal antibody , immunohistochemistry , medicine , antigen , monoclonal , pathology , cancer research , antibody , oncology , immunology , b cell , cancer
Although diffuse large B‐cell lymphoma (DLBCL) is the most common type of non‐Hodgkin lymphoma, it is both clinically and morphologically heterogenous. The present study investigates the significance of survivin and a novel monoclonal antibody (MAb), T332, immunohistochemically for predicting the prognoses of DLBCL and its subtypes classified as germinal center B‐cell‐like type (GCB) and non‐GCB type (NGCB) based on the expression profiles of CD10, bcl‐6, and MUM1. A total of 60 cases of DLBCL (GCB, n = 22; NGCB, n = 38) were examined for the expression of survivin and T332 antigen. Survivin + DLBCL had a significantly worse prognosis ( P = 0.01) than survivin – cases, as already reported, while survivin + GCB or NGCB tended to have poor prognoses ( P = 0.06 and 0.07, respectively). However, T332 + DLBCL and NGCB had significantly more unfavorable prognoses than T332 – cases ( P = 0.01 and 0.02, respectively) while there was no significant survival difference between the T332 + and T332 – groups of GCB ( P = 0.11). Interestingly DLBCL coexpressing survivin and T332 ( n = 13) had a significantly worse prognosis ( P = 0.009) than the remaining single positive and double negative cases ( n = 31). In conclusion, survivin and the novel MAb, T332, might be a good predictor of DLBCL and its subtypes.